Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy (CRYOKID)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03433326
Recruitment Status : Unknown
Verified February 2018 by Anna Linda Zignego, University of Florence. Recruitment status was: Not yet recruiting
CryoKid is a no-profit, multi-center, single-arm, open-label, pilot study. The study aims to evaluate the tolerability of MK-8742 (Elbasvir) / MK-5172 (Grazoprevir) administrated for 12 weeks without Ribavirin in patients with HCV chronic hepatitis (G1b and G4) and cryoglobulinemic nephropathy.
Percentage of participants achieving sustained virologic response 12 weeks after completing treatment (SVR12)
Secondary Outcome Measures :
SVR24 [ Time Frame: march 2018-december 2018 ]
Percentage of participants achieving Sustained Virologic Response 24 weeks after ending study treatment (SVR 24)
Clinical response: improvement or disappearance of MC clinical and biochemical stigmata [ Time Frame: march 2018-december 2018 ]
Clinical response: improvement or disappearance of MC clinical and biochemical stigmata at the EOT, at week 12 and week 24 of follow-up. Improvement of the renal function at week 4, week 8, EOT at week 12 and week 24 of follow-up.
Tolerability: Number of participants experiencing an adverse event (AE) [ Time Frame: march 2018-may 2018 ]
Tolerability: Number of participants experiencing an adverse event (AE)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
G1b and G4 patients with HCV-related Cryoglobulinemic Nephropathy
Informed consent form signed,
Male or female at least 18 years of age at time of Screening.
Chronic infection with Hepatitis C virus G1b
Chronic infection with Hepatitis C virus G4 naïve, and experienced with baseline HCV RNA level <800,000 IU/ml
Metavir score ranging between F0-F4 (with Child-Pugh score ranging from A5 to A6)
Diagnosis of mixed cryoglobulinemia MC (type III or II) according to standard criteria
Chronic renal impairment due to cryoglobulinemic nephropathy. Subjects with renal impairment will include CKD Stage 5 (eGFR < 15mL/min or dialysis dependent), CKD Stage 4 (eGFR 15-29 mL/min), CKD Stage 3 eGFR (30-59 mL/min) and CKD Stage 2 (60-89 mL/min) HCV patients.
Albumin level ≥ 3.0 g/dl,
Platelet count ≥ 75 x 103/μL.
Age <18 years
Chronic infection with Hepatitis C virus G4 experienced with baseline HCV RNA level >800,000 IU/ml
Patients with HCV genotype 1a, 2, 3, 5, 6,
Coexistence of life-threatening condition(s) unrelated to MC
Diagnosis of malignancy
Pregnancy or breast feeding.
Child-Pugh score > A6
Decompensated cirrhosis or previous decompensation
Platelet count < 75 x 103/μL
Albumin level < 3 g/l
Co-infection with more than one HCV genotype.
Any serious or active medical illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance
HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive)
Known hypersensitivity to Grazoprevir, Elbasvir or any of its components